Biostatistics, Epidemiology, and Medical Literature Practice Questions — USMLE Step 3

Question 1Question →

A clinical research steering committee is reviewing proposed modifications to the design of an ongoing randomized controlled trial evaluating a new medical therapy for heart failure. Match each proposed trial design modification with its primary impact on the study's statistical power or error rates.

Click a left item, then click its matching right item

Show answer & explanation

Answer

Dichotomizing endpoints decreases power; unadjusted interim analyses inflate Type I error; targeting a smaller effect size without increasing sample size increases Type II error; and enrolling a higher-risk population increases power.

Each proposed modification alters the mathematical framework of the trial. Dichotomizing continuous data wastes information, lowering power. Repeated testing inflates the chance of a random false positive (Type I error). Attempting to detect a smaller effect without adding subjects reduces power (increasing Type II error). Selecting patients more likely to have the event increases the overall event count, which directly drives statistical power.

Step-by-Step Solution

1

Analyze the impact of dichotomizing a continuous variable.

It matches with decreasing statistical power due to loss of granularity.

Continuous variables contain more data points and variability; categorizing them discards within-group variance information, resulting in reduced statistical power.

2

Analyze the impact of multiple interim analyses.

It matches with inflating the Type I error rate.

Testing data multiple times without appropriate statistical adjustments (like alpha-spending functions) increases the cumulative probability of finding a false positive by chance.

3

Analyze the impact of seeking a smaller effect size with a fixed sample size.

It matches with increasing the Type II error rate.

A smaller difference is mathematically harder to detect. If the sample size is not proportionally increased, the study will be underpowered, leading to a higher beta (Type II error).

4

Analyze the impact of increasing the baseline event rate.

It matches with enhancing statistical power.

In clinical trials (especially time-to-event or binary outcome trials), statistical power is driven by the absolute number of events observed, not just the number of patients. Higher baseline risk yields more events.

Key Concept

Understanding how trial design modifications (endpoint selection, interim analyses, effect size estimation, and patient selection) impact Type I error, Type II error, and statistical power.

Question 2Question →

A clinical research committee is reviewing a series of proposals for upcoming therapeutic trials. As part of the methodological review, the biostatistician evaluates how specific study design modifications will impact error rates and statistical power. Match each proposed trial modification with its primary statistical consequence.

Click a left item, then click its matching right item

Show answer & explanation

Answer

Decreasing

\alpha

matches with reducing false rejections but increasing

\beta

error. Increasing sample size matches with narrowing standard error. A smaller effect size matches with shifting the alternative curve closer to the null. Decreasing variance matches with reducing data spread and increasing power at the cost of generalizability.

Each modification predictably alters the statistical mechanics of a clinical trial. Lowering

\alpha

decreases Type I errors but increases Type II errors. Increasing sample size reduces standard error, boosting statistical power. A smaller effect size brings the null and alternative distributions closer, dropping power. Reducing variance narrows the distributions, increasing power but limiting external validity.

Step-by-Step Solution

1

Analyze the impact of lowering the alpha threshold.

Matches with decreased Type I error and increased Type II (

\beta

) error.

Alpha represents the Type I error rate; lowering it requires stronger statistical evidence to reject the null, making it more likely to miss a true difference.

2

Analyze the impact of increasing sample size (

n

).

Matches with decreased standard error and increased power.

Standard error is inversely proportional to the square root of

n

. A larger

n

narrows the distributions, making differences easier to detect.

3

Analyze the impact of a smaller true effect size.

Matches with curves shifting closer together and decreased power.

Effect size is the actual difference between groups. A smaller difference means more overlap between the null and alternative distributions, increasing Type II error.

4

Analyze the impact of decreasing population variance.

Matches with reduced data spread and increased power.

Less variance means narrower curves and less overlap, which improves the ability to detect a difference, though highly restricted cohorts may not represent the general population.

Key Concept

The interconnected relationships between alpha, beta, statistical power, sample size, effect size, and variance in hypothesis testing.

Estimated Time:1m 30s

Question 3Question →

A retrospective cohort study investigates the association between a new oral hypoglycemic agent and the risk of severe hypoglycemia. The initial unadjusted analysis shows a relative risk (RR) of 2.8 (95% CI: 1.9 - 3.7). The researchers note that patients prescribed the new agent generally have a longer duration of diabetes. They decide to stratify the patients into two groups: those with diabetes for less than 10 years and those with diabetes for 10 years or more. Following stratification, the RR for severe hypoglycemia associated with the new agent is 1.0 (95% CI: 0.8 - 1.2) in both stratified groups. Which of the following best describes the role of diabetes duration in this study?

Confounding variable

Effect modifier

Dependent variable

Cognitive bias

Measurement bias

Show answer & explanation

Answer: Confounding variable

Answer

Confounding variable

The correct answer is Confounding variable. Confounding occurs when a third variable is associated with both the exposure and the outcome, creating a false association. The classic method to identify confounding is stratification. If stratifying by the suspected third variable causes the original association to disappear (the relative risks in the strata become approximately 1.0), then that third variable is a confounder.

Step-by-Step Solution

1

Analyze the crude (unadjusted) relative risk.

The unadjusted RR is 2.8, suggesting a significant positive association between the new drug and severe hypoglycemia.

Establishing the baseline association is necessary before evaluating the impact of stratification.

2

Evaluate the results after stratifying by diabetes duration.

In both the <10 years and ≥10 years strata, the RR becomes 1.0, meaning there is no association within the specific subgroups.

Stratification helps distinguish whether a third variable is driving the observed crude association or modifying it.

3

Interpret the change in relative risk.

Because the association completely disappears upon stratification, the original crude association was entirely driven by the unequal distribution of the third variable (diabetes duration) between the exposure groups.

This pattern (crude association disappears upon stratification) is the defining epidemiological signature of a confounding variable.

Key Concept

Confounding versus Effect Modification

Estimated Time:1m 0s

Question 4Question →

A clinical investigator is studying the effect of a newly developed ACE inhibitor on serum potassium levels. The study enrolls 50 adult patients with essential hypertension. Each patient has their baseline serum potassium level measured prior to starting the medication. After four weeks of daily therapy, a second serum potassium measurement is obtained for each patient. The investigator wants to evaluate if there is a statistically significant change in serum potassium levels from baseline. Depending on whether the data follows a normal distribution, which of the following statistical tests are appropriate for analyzing the results of this study? Select all that apply.

Select all that apply

Paired t-test

Wilcoxon signed-rank test

Independent samples t-test

Chi-square test

Kruskal-Wallis test

Show answer & explanation

Answer: Paired t-test; Wilcoxon signed-rank test

Answer

The correct statistical tests for this scenario are the paired t-test (for normally distributed data) and the Wilcoxon signed-rank test (for non-normally distributed data).

The study evaluates a continuous variable (serum potassium) collected from a single group of patients at two distinct time points (baseline and four weeks later). Because the measurements are taken from the exact same individuals, the data is paired (dependent). The appropriate test for analyzing the difference in means for paired continuous data is the paired t-test, provided the differences are normally distributed. If the distribution is skewed or non-normal, the correct non-parametric alternative is the Wilcoxon signed-rank test.

Step-by-Step Solution

1

Identify the type of data being analyzed in the study.

The outcome variable is serum potassium level, which is a continuous quantitative variable.

Statistical test selection depends fundamentally on whether the primary outcome is continuous, ordinal, or categorical.

2

Determine the relationship between the study comparison groups.

The study compares measurements taken from the exact same individuals at two distinct time points (baseline and after four weeks). This constitutes paired, or matched, data.

Statistical tests differ based on whether the groups being compared are independent (different patients) or dependent/paired (the same patients).

3

Select the appropriate parametric and non-parametric tests for the data characteristics.

For paired continuous data across two time points, the paired t-test is used for normally distributed data, and the Wilcoxon signed-rank test is the non-parametric equivalent.

The question asks for the appropriate tests depending on whether the data follows a normal distribution, requiring the identification of both the parametric and non-parametric options.

Key Concept

Selecting statistical tests for paired continuous variables

Question 5Question →

An academic medical center is organizing a retrospective cohort investigation to assess the risk of incident chronic kidney disease (CKD) associated with a newly introduced antihypertensive agent compared to standard angiotensin-converting enzyme (ACE) inhibitors. The principal investigator hypothesizes that the novel agent is highly protective against CKD in non-diabetic patients, but paradoxically accelerates renal function decline in patients with pre-existing diabetes mellitus.

To accurately test this specific hypothesis regarding the differential impact of diabetes, which of the following methodological and analytical approaches MUST be integrated into the study design? (Select all that apply)

Select all that apply

Conduct a stratified analysis that calculates the relative risk of incident chronic kidney disease separately for patients with and without diabetes.

Incorporate a statistical interaction term between medication type and baseline diabetes status within a multivariable regression model.

Perform propensity score matching for diabetes status to ensure baseline equivalence before calculating a single, pooled relative risk.

Restrict the study population entirely to patients without baseline diabetes to eliminate its influence on the primary outcome.

Utilize a paired t-test to compare the mean continuous decline in estimated glomerular filtration rate between the independent novel agent and ACE inhibitor groups.

Show answer & explanation

Answer: Conduct a stratified analysis that calculates the relative risk of incident chronic kidney disease separately for patients with and without diabetes.; Incorporate a statistical interaction term between medication type and baseline diabetes status within a multivariable regression model.

Answer

The investigators must conduct a stratified analysis calculating risks separately for diabetics and non-diabetics, and incorporate a statistical interaction term between medication type and diabetes status in their regression model.

The principal investigator is explicitly describing effect modification—where the effect of the exposure (medication) on the outcome (incident CKD) depends on a third variable (diabetes). To properly assess effect modification, investigators must use methods that allow the differing effects to be observed independently. Conducting a stratified analysis achieves this by calculating the risk separately within the diabetic and non-diabetic groups. Additionally, incorporating a statistical interaction term in a multivariable regression model provides a formal statistical test to determine if the difference in effect between the two strata is statistically significant.

Step-by-Step Solution

1

Identify the core epidemiological concept described in the principal investigator's hypothesis.

The hypothesis states that a drug has a different effect based on a third variable (diabetes status). This defines 'effect modification' (interaction), not confounding.

Recognizing the difference between confounding (a distortion to be eliminated) and effect modification (a biological reality to be described) is crucial for selecting the right study design.

2

Evaluate which methodological approaches are designed to detect and describe effect modification.

Stratified analysis (calculating effects separately for each subgroup) and interaction terms in regression models are standard methods for assessing effect modification.

These methods allow the differing effects to be observed and statistically quantified.

3

Evaluate why the other options are incorrect for this specific hypothesis.

Matching and restriction are methods used to control for confounding by eliminating the variable's influence. A paired t-test is an incorrect statistical test for independent groups.

Applying confounding control methods to an effect modifier masks the very phenomenon the study aims to investigate.

Key Concept

Effect modification occurs when the magnitude or direction of an association between an exposure and an outcome varies according to the level of a third variable. It must be evaluated using stratified analysis or interaction terms, whereas methods like matching or pooling are used to eliminate confounding.

Question 6Question →

A randomized, double-blind, placebo-controlled clinical trial is conducted to evaluate the efficacy and safety of Agent Z, a novel biologic therapy, in adults with severe plaque psoriasis. The primary efficacy endpoint is the proportion of patients achieving a $75\%$ reduction in the Psoriasis Area and Severity Index (PASI 75) at week 16. The primary safety endpoint is the incidence of serious infections over the same period. The trial enrolls $800$ patients, randomized equally to receive either Agent Z or a placebo.

The trial results at 16 weeks are shown in the table below:

Outcome	Agent Z ( $n = 400$ )	Placebo ( $n = 400$ )	$95\%$ CI of Absolute Difference*
Achieved PASI 75	$240$	$40$	$44.4\%$ to $55.6\%$
Developed serious infection	$12$	$8$	$-1.2\%$ to $3.2\%$

*\*Note: Absolute difference is calculated as the incidence in the Agent Z group minus the incidence in the placebo group.*

Based on these results, which of the following statements most accurately describes the clinical impact of Agent Z compared to placebo?

For every

10

patients treated with Agent Z,

1

additional patient achieves PASI 75; however, there is insufficient evidence to conclude that Agent Z increases the risk of serious infections.

For every

6

patients treated with Agent Z,

1

additional patient achieves PASI 75; however, there is insufficient evidence to conclude that Agent Z increases the risk of serious infections.

For every

2

patients treated with Agent Z,

1

additional patient achieves PASI 75; however, there is insufficient evidence to conclude that Agent Z increases the risk of serious infections.

For every

2

patients treated with Agent Z,

1

additional patient achieves PASI 75, and for every

100

patients treated,

1

additional serious infection occurs.

For every

2

patients treated with Agent Z,

1

additional patient achieves PASI 75, and for every

33

patients treated,

1

additional serious infection occurs.

Show answer & explanation

Answer: For every $2$ patients treated with Agent Z, $1$ additional patient achieves PASI 75; however, there is insufficient evidence to conclude that Agent Z increases the risk of serious infections.

Answer

The most accurate statement is that for every 2 patients treated with Agent Z, 1 additional patient achieves PASI 75; however, there is insufficient evidence to conclude that Agent Z increases the risk of serious infections.

The correct answer accurately calculates the Number Needed to Treat (NNT) and correctly identifies that the adverse event data is not statistically significant. First, the Absolute Benefit Increase (ABI) for achieving PASI 75 is calculated as the incidence in the Agent Z group (

\frac{240}{400} = 60\%

) minus the incidence in the placebo group (

\frac{40}{400} = 10\%

), which equals

50\%

(

0.50

). The NNT is the reciprocal of the ABI (

\frac{1}{0.50} = 2

). Second, while there is a numerically higher rate of serious infections in the Agent Z group (

3\%

vs

2\%

), the

95\%

confidence interval for this absolute difference (

-1.2\%

to

3.2\%

) crosses

0

. An absolute difference CI that crosses

0

indicates that the result is not statistically significant (

p > 0.05

). Therefore, there is insufficient evidence to conclude that Agent Z increases the risk of serious infections, and calculating a Number Needed to Harm (NNH) is epidemiologically inappropriate.

Step-by-Step Solution

1

Calculate the Absolute Benefit Increase (ABI) for the primary efficacy endpoint.

Agent Z incidence =

\frac{240}{400}

(

60\%

). Placebo incidence =

\frac{40}{400}

(

10\%

). ABI =

60\% - 10\% = 50\%

(

0.50

).

To determine the absolute clinical benefit attributable to the intervention compared to the control.

2

Calculate the Number Needed to Treat (NNT).

NNT =

\frac{1}{0.50} = 2

.

The NNT represents the number of patients who need to receive the experimental treatment to achieve one additional positive outcome. It is always the reciprocal of the absolute difference in efficacy.

3

Evaluate the statistical significance of the safety outcome (serious infections).

The

95\%

confidence interval for the absolute difference in serious infections ranges from

-1.2\%

to

3.2\%

. Because this interval includes

0

, the difference is not statistically significant.

If a

95\%

CI for an absolute difference between two groups crosses

0

(the null value for differences), the result is not statistically significant at the

p < 0.05

level.

4

Synthesize the findings into a clinical conclusion.

The NNT is

2

, and no valid Number Needed to Harm (NNH) can be established.

It is incorrect to report an NNH for an outcome that has not been proven to be statistically different from placebo, as any observed numerical difference is likely due to chance.

Key Concept

Calculating Number Needed to Treat (NNT) from absolute risk differences and interpreting Confidence Intervals to determine statistical significance before calculating Number Needed to Harm (NNH).

Question 7Question →

To evaluate the efficacy of a novel immunomodulator in preventing clinical relapses among patients with relapsing-remitting multiple sclerosis, researchers conduct a phase III, placebo-controlled, double-blind trial. A total of $2,000$ enrolled patients are randomized in a 1:1 ratio to receive either the novel immunomodulator or a placebo. After two years of continuous follow-up, $140$ patients in the placebo arm and $95$ patients in the intervention arm experienced at least one clinical relapse. In their primary analysis, the investigators report the absolute risk reduction alongside a 95% confidence interval of $0.021$ to $0.069$ .

Determine the number of patients that must be treated with the novel immunomodulator to prevent one additional clinical relapse, and appropriately characterize the statistical significance based on the reported absolute risk reduction confidence interval.

23 patients; the finding is statistically significant because the confidence interval for the risk difference excludes 0.

22 patients; the finding is statistically significant because the confidence interval for the risk difference excludes 0.

23 patients; the finding is statistically significant because the confidence interval for the risk difference excludes 1.

22 patients; the finding is statistically significant because the confidence interval for the risk difference excludes 1.

4 patients; the finding is statistically significant because the confidence interval for the risk difference excludes 0.

Show answer & explanation

Answer: 23 patients; the finding is statistically significant because the confidence interval for the risk difference excludes 0.

Answer

23 patients; the finding is statistically significant because the confidence interval for the risk difference excludes 0.

The correct answer accurately calculates the NNT as 23 and correctly identifies 0 as the null value for an absolute risk difference. First, the ARR is determined by finding the difference in event rates:

140/1000

(

14\%

) in the placebo group minus

95/1000

(

9.5\%

) in the intervention group, yielding an ARR of

4.5\%

(

0.045

). The NNT is the inverse of the ARR (

1 / 0.045 = 22.22

). In clinical biostatistics, NNT must always be rounded up to the next highest whole number to guarantee that the desired clinical benefit (preventing one relapse) is achieved, making the correct NNT 23. Furthermore, because ARR is an absolute difference, the null value indicating no effect is 0. The reported 95% CI of

0.021

to

0.069

does not cross 0, indicating a statistically significant reduction in risk.

Step-by-Step Solution

1

Calculate the Control Event Rate (CER) and Experimental Event Rate (EER).

CER =

140 / 1000 = 0.14

(

14\%

), EER =

95 / 1000 = 0.095

(

9.5\%

).

Incidence rates for both groups must be derived from the raw patient data before calculating comparative measures.

2

Calculate the Absolute Risk Reduction (ARR).

ARR = CER - EER =

0.14 - 0.095 = 0.045

(

4.5\%

).

ARR represents the absolute difference in the risk of the primary outcome between the placebo and intervention groups.

3

Calculate the Number Needed to Treat (NNT).

NNT =

1 / \text{ARR} = 1 / 0.045 = 22.22

. Rounding up yields

23

.

NNT is the inverse of the ARR. It must always be rounded up to the next whole number to guarantee the prevention of one additional adverse event.

4

Interpret the statistical significance of the confidence interval.

The 95% CI (

0.021

to

0.069

) excludes

0

.

For an absolute risk difference (such as ARR), the null value indicating no treatment effect is 0. Because the entire interval sits above 0, the finding is statistically significant.

Key Concept

Calculating Number Needed to Treat (NNT) and Interpreting Confidence Intervals for Absolute Risk

Question 8Question →

A consortium of community hospitals initiates a prospective, randomized controlled study evaluating an early-ambulation protocol for postoperative orthopedic patients. The primary outcome is the mean length of hospital stay. Initial statistical modeling determined that 450 participants are needed to achieve $80\%$ power to detect a 1.5-day difference between the intervention and standard care groups, utilizing a two-tailed $\alpha$ of $0.05$ .

Halfway through the enrollment period, an independent data monitoring committee conducts a blinded interim audit. They discover that the standard deviation for the length of hospital stay across all enrolled patients is nearly double the estimate originally derived from preliminary pilot data. The trial sponsors mandate that the study must conclude precisely when the original enrollment target of 450 participants is reached, and no alterations to the predetermined significance threshold are permitted.

Based on the newly discovered population parameters, which of the following is the most accurate statement regarding the trial's operating characteristics?

The study's capacity to demonstrate a genuine reduction in length of stay is compromised.

The risk of erroneously adopting an ineffective ambulation protocol is substantially elevated.

The presence of baseline variance inflation indicates unrecognized effect modification.

The proportion of true positive findings among all statistically significant results will increase.

The predefined threshold for rejecting the null hypothesis functionally decreases.

Show answer & explanation

Answer: The study's capacity to demonstrate a genuine reduction in length of stay is compromised.

Answer

The study's capacity to demonstrate a genuine reduction in length of stay is compromised.

The correct answer recognizes that statistical power is fundamentally dependent on the variability of the data. Power is the probability of correctly rejecting a false null hypothesis (i.e., successfully detecting a true clinical effect). The standard error of the difference between two means is directly proportional to the standard deviation of the population. When the interim audit revealed a doubled standard deviation, the standard error increased. A larger standard error narrows the test statistic for any given absolute difference, causing the corresponding confidence interval to widen. Because the sample size and alpha level are strictly capped, this inflation in variance mathematically reduces the study's statistical power. Consequently, the study is now more likely to commit a Type II error (failing to detect the 1.5-day reduction even if it truly exists).

Step-by-Step Solution

1

Identify the primary parameters that determine statistical power in a clinical trial.

Statistical power depends on the alpha level, sample size, effect size (the 1.5-day difference), and population variance (standard deviation).

Understanding the components of the power equation is required to predict how changes in one variable affect the overall test.

2

Analyze the impact of the interim audit findings on these parameters.

The sample size (450) and alpha (0.05) are fixed. The standard deviation is now known to be nearly double the initial estimate. The variance has increased significantly.

Isolating the changed variable allows for direct evaluation of its mathematical consequence.

3

Determine how increased variance affects statistical power.

A higher standard deviation increases the standard error of the mean difference. A larger standard error results in a smaller test statistic (e.g., t-value) for any given effect size, making it harder to achieve statistical significance. This equates to a loss of statistical power.

Lower power means a higher probability of a Type II error (failing to reject a false null hypothesis), thereby compromising the study's ability to detect a true difference.

Key Concept

Statistical power is inversely related to population variance; as standard deviation increases, standard error increases, resulting in diminished power to detect a true clinical effect.

Question 9Question →

A consortium of neuroscientists is planning a study to evaluate whether elevated levels of a newly identified structural neurofilament protein in the serum of healthy young adults increases the risk of developing a rare variant of early-onset frontotemporal dementia (FTD) later in life. The incidence of this specific FTD variant is approximately $1$ in $250,000$ person-years. The investigators have obtained approval to access a national military biobank that contains baseline serum samples and $40$ years of continuous, comprehensive electronic health records for over $3$ million service members. However, the novel mass spectrometry assay required to quantify the neurofilament protein is highly resource-intensive and prohibitively expensive, preventing the analysis of all available biobank samples. Which of the following study designs is most appropriate to efficiently investigate this association while minimizing selection bias?

Prospective cohort study

Retrospective cohort study

Nested case-control study

Case-crossover study

Case-control study recruiting healthy community volunteers

Show answer & explanation

Answer: Nested case-control study

Answer

The most appropriate study design is a nested case-control study.

A nested case-control study is the optimal design for this scenario. It involves identifying all incident cases of the rare disease (FTD) that developed over the

40

years within the defined retrospective cohort (the

3

million service members). These cases are then matched with a random sample of controls from the same cohort who were at risk at the time the cases were diagnosed. Because the expensive exposure assay is performed only on the cases and the selected controls rather than the entire cohort of

3

million, this design is highly cost-effective and efficient. Furthermore, because the controls are drawn from the exact same well-defined source population as the cases, the selection bias that typically plagues traditional case-control studies is virtually eliminated.

Step-by-Step Solution

1

Analyze the characteristics of the outcome and the exposure.

The outcome (FTD variant) is exceptionally rare (

1

in

250,000

person-years), and the exposure measurement (mass spectrometry assay for the neurofilament protein) is prohibitively expensive.

Understanding the rarity and resource constraints dictates which epidemiological designs are statistically and financially feasible.

2

Evaluate the available data source.

The researchers have access to an established, massive cohort of

3

million individuals with

40

years of continuous follow-up and stored baseline serum samples.

The availability of a well-defined cohort provides an opportunity to conduct retrospective analyses without waiting decades for prospective follow-up.

3

Determine the optimal study design to overcome the cost constraint.

A nested case-control study allows researchers to identify all incident FTD cases within the

3

million-person cohort and match them with a randomly selected subset of healthy controls from the exact same cohort.

By only analyzing the serum of the cases and the selected subset of controls, the researchers avoid the impossible cost of running the assay on all

3

million samples (which a retrospective cohort design would require).

4

Assess how the design minimizes selection bias.

Because the controls in a nested case-control study are drawn from the same precise source population (the military biobank) as the cases, differential selection bias is inherently minimized.

Traditional case-control studies that recruit external healthy volunteers often suffer from severe selection bias due to unmeasured baseline differences between populations.

Key Concept

Nested case-control studies are the optimal epidemiologic design for investigating a rare outcome within a pre-existing cohort when the measurement of the exposure is highly expensive or resource-intensive.

Question 10Question →

An infectious disease epidemiology unit is investigating an outbreak of carbapenem-resistant *Enterobacteriaceae* (CRE) bacteremia. They aim to evaluate whether prior exposure to specific broad-spectrum antibiotics is a risk factor. Over a 3-year period, the researchers identify $120$ patients who developed CRE bacteremia during their hospitalization. For each of these patients, they select three control patients from the same hospital who did not develop CRE bacteremia, matching them exactly by age, admission date, and hospital ward. The investigators then retrospectively review the electronic medical records to compare the duration and types of antibiotics administered to both groups prior to the index date.

Which of the following statements correctly describe the methodological characteristics or appropriate analytical requirements for this study design? (Select all that apply)

Select all that apply

The investigators must use an odds ratio rather than relative risk to estimate the magnitude of association between prior antibiotic use and CRE bacteremia.

The appropriate statistical analysis requires the use of conditional logistic regression to account for the variables matched during the design phase.

The researchers can appropriately use an independent two-sample t-test to determine if there is a statistically significant difference in the binary outcome of CRE bacteremia between the exposed and unexposed groups.

Because the study carefully matched patients by admission date and ward, the positive predictive value (PPV) of prior broad-spectrum antibiotic use for developing CRE bacteremia can be directly calculated from the study cohort.

In an unmatched version of this study, observing significantly different odds ratios for CRE bacteremia between different hospital wards during a stratified analysis would indicate that the hospital ward is acting as a confounding variable rather than an effect modifier.

Show answer & explanation

Answer: The investigators must use an odds ratio rather than relative risk to estimate the magnitude of association between prior antibiotic use and CRE bacteremia.; The appropriate statistical analysis requires the use of conditional logistic regression to account for the variables matched during the design phase.

Answer

The correct statements recognize that this matched case-control design requires the use of an odds ratio to estimate association and necessitates conditional logistic regression for proper analysis.

The described scenario is a matched case-control study. In case-control studies, subjects are selected based on their disease status rather than their exposure status. Because the total population at risk is unknown, researchers cannot calculate true disease incidence, and therefore cannot calculate relative risk (RR). Instead, the odds ratio (OR) must be used to estimate the magnitude of the association. Furthermore, when a case-control study employs matching during the design phase (such as matching cases and controls precisely by age, admission date, and ward), the subsequent statistical analysis must account for this matching to prevent the association from being biased toward the null hypothesis. Conditional logistic regression is the required statistical method for analyzing matched case-control data.

Step-by-Step Solution

1

Identify the primary study design from the methodology described in the stem.

The researchers started with known outcomes (CRE bacteremia cases), selected controls without the outcome, matched them

1:3

, and looked backward in time for exposure (antibiotics). This is a matched case-control study.

Correctly identifying the study architecture is a prerequisite for knowing which statistical measures and analyses are valid.

2

Determine the correct measure of association for this design.

Relative risk (RR) cannot be calculated because the study does not track an at-risk population forward to calculate true incidence. The odds ratio (OR) must be used to estimate the association.

Case-control studies artificially determine the ratio of cases to controls, which distorts incidence and prevalence metrics.

3

Determine the appropriate statistical test needed for the matched data.

Conditional logistic regression must be utilized instead of standard unadjusted tests or standard logistic regression.

Matching during the study design phase forces the cases and controls to have identical distributions of the matched variables (age, date, ward). This introduces an artificial bias that must be accounted for mathematically to avoid biasing the OR toward the null (1.0).

Key Concept

Matched case-control studies require odds ratios for association and conditional logistic regression for valid statistical analysis.

Question 11Question →

A randomized controlled trial is evaluating a novel intensive lifestyle intervention against standard care for reducing fasting blood glucose in adults with prediabetes. The primary outcome is the mean change in fasting blood glucose after 6 months. Initial sample size calculations indicate that 300 participants are required to provide 80% statistical power to detect a 10 mg/dL difference between groups, using a two-sided $\alpha$ of 0.05 and an anticipated standard deviation (SD) of 20 mg/dL.

Prior to patient enrollment, the central laboratory transitions to a new, highly precise point-of-care assay. A pilot validation study confirms that this new assay reduces the anticipated SD of the fasting blood glucose measurements from 20 mg/dL to 10 mg/dL. The investigators decide to proceed with the originally planned sample size of 300 participants without altering the $\alpha$ level.

Assuming the true effect size remains 10 mg/dL, which of the following best describes the statistical impact of utilizing the new laboratory assay?

The primary outcome must now be analyzed using a Chi-square test rather than a Student's t-test.

The positive predictive value of a statistically significant finding will become independent of the pre-test probability of the intervention's efficacy.

The probability of committing a Type I (

\alpha

) error will decrease because of the reduced measurement variability.

The probability of committing a Type II (

\beta

) error will decrease.

The increased precision will allow researchers to interpret baseline demographic confounders as effect modifiers.

Show answer & explanation

Answer: The probability of committing a Type II ( $\beta$ ) error will decrease.

Answer

The probability of committing a Type II (

\beta

) error will decrease.

The correct answer accurately states that the probability of a Type II error will decrease. Statistical power is the probability of correctly rejecting the null hypothesis when a true difference exists (Power = 1 -

\beta

). Power is determined by the

\alpha

level, sample size, effect size, and variance (standard deviation). Because the new assay reduces the standard deviation by half, the signal-to-noise ratio improves dramatically. With sample size and

\alpha

held constant, this increases the statistical power. An increase in power mathematically dictates a corresponding decrease in

\beta

, the probability of committing a Type II error.

Step-by-Step Solution

1

Identify the trial parameters being modified.

The standard deviation (SD) is decreasing from 20 mg/dL to 10 mg/dL, while sample size (N = 300), effect size (10 mg/dL), and alpha (0.05) remain constant.

To determine how statistical properties are affected, you must isolate the changed variable.

2

Relate the change in SD to statistical power.

A smaller SD reduces the standard error of the mean difference, thereby increasing the precision of the estimate and increasing the statistical power of the trial.

Statistical power is inversely proportional to variance; lower variance (SD) yields higher power.

3

Correlate statistical power to error types.

Power is defined as 1 -

\beta

(where

\beta

is the probability of a Type II error). Therefore, an increase in power mathematically guarantees a decrease in the probability of a Type II error.

To select the correct option describing the statistical impact.

Key Concept

Reducing the variance (standard deviation) of an outcome measure, while keeping sample size and effect size constant, increases statistical power and decreases the probability of a Type II error.

Question 12Question →

A physician is reviewing a pharmaceutical advertisement for a newly approved oral anticoagulant, 'Novanoxaban,' indicated for stroke prevention in non-valvular atrial fibrillation. The promotional material highlights a recent randomized, double-blind, non-inferiority trial comparing Novanoxaban to the standard of care. The advertisement includes a forest plot showing a primary efficacy endpoint hazard ratio (HR) of $1.10$ with a $95\%$ confidence interval (CI) of $0.95$ to $1.25$ . The pre-specified non-inferiority margin ( $\Delta$ ) is set at an HR of $1.30$ . The bolded text in the brochure concludes: 'Novanoxaban is highly effective, demonstrating non-inferiority to standard of care based on a robust intention-to-treat (ITT) analysis, despite a $20\%$ loss to follow-up in both arms.' Which of the following is the most significant methodological concern regarding the interpretation of this drug advertisement?

The reliance on an intention-to-treat analysis with high attrition biases the treatment effect toward equivalence, potentially falsely confirming non-inferiority.

The confidence interval crosses

1.0

, indicating that unmeasured confounding variables have made the experimental drug statistically inferior.

The high loss to follow-up directly decreases the positive predictive value of the primary endpoint, rendering the results clinically invalid.

Evaluating hazard ratios in a study with

20\%

attrition requires the use of an independent t-test rather than survival analysis models.

The presentation of the non-inferiority margin introduces an anchoring bias that masks the true absolute risk reduction of the medication.

Show answer & explanation

Answer: The reliance on an intention-to-treat analysis with high attrition biases the treatment effect toward equivalence, potentially falsely confirming non-inferiority.

Answer

The reliance on an intention-to-treat analysis with high attrition biases the treatment effect toward equivalence, potentially falsely confirming non-inferiority.

In randomized controlled trials, the intention-to-treat (ITT) analysis includes all subjects based on their initial random assignment, regardless of whether they completed the study or adhered to the protocol. In superiority trials, ITT is considered the gold standard because non-adherence and loss to follow-up tend to dilute the treatment effect, making it harder to establish a statistically significant difference (a conservative approach). However, in non-inferiority trials, the goal is to prove that the new treatment is 'not unacceptably worse' than the standard. If a high dropout rate (

20\%

) dilutes the treatment effect, the two study arms will artificially look more similar to each other. This bias toward the null makes it dangerously easier to cross the threshold for non-inferiority, increasing the risk of a Type I error (falsely concluding non-inferiority). For this reason, FDA and clinical guidelines mandate that non-inferiority trials demonstrate robustness in both ITT and Per-Protocol (PP) analyses.

Step-by-Step Solution

1

Analyze the trial design and endpoint data provided in the stem.

The trial is a non-inferiority study with an upper CI bound (

1.25

) that falls below the non-inferiority margin (

1.30

).

Understanding the baseline parameters confirms that, superficially, the drug meets the criteria for non-inferiority.

2

Evaluate the stated analytical method and the attrition rate.

The advertisement relies on an intention-to-treat (ITT) analysis despite a significant

20\%

loss to follow-up.

High attrition or non-adherence can significantly alter the interpretation of trial data depending on the statistical approach.

3

Determine the impact of ITT analysis in the specific context of a non-inferiority trial.

ITT analysis includes all randomized patients regardless of adherence. When attrition is high, this dilutes the observed differences between the groups, biasing the result toward the null (equivalence).

While ITT is conservative in superiority trials (making it harder to prove a difference), it is anti-conservative in non-inferiority trials (making it easier to falsely prove equivalence). A per-protocol analysis is typically required alongside ITT to confirm validity.

Key Concept

Intention-to-Treat (ITT) vs. Per-Protocol Analysis in Non-Inferiority Trials

Question 13Question →

Match each clinical research scenario with the specific epidemiological concept or type of bias it best illustrates.

Click a left item, then click its matching right item

Show answer & explanation

Answer

The scenarios match to Length-time bias, Effect modification, Confounding, Attrition bias, and Recall bias respectively.

Each scenario accurately depicts a distinct epidemiological concept. Length-time bias involves over-representing slow-growing diseases. Effect modification shows different risk ratios in different strata due to a biological interaction. Confounding shows a false association that disappears when the third variable is stratified. Attrition bias occurs when dropouts differ from completers. Recall bias occurs when cases remember past exposures differently than controls.

Step-by-Step Solution

1

Analyze the cancer screening scenario

Identifies length-time bias

Screening tests tend to diagnose diseases with longer preclinical phases (less aggressive), making it seem like survival is improved simply because benign cases are overrepresented in the screened cohort.

2

Analyze the biologic agent scenario

Identifies effect modification

When an exposure has a different magnitude of effect on different subgroups (strata), it is an inherent biological interaction, not a flaw to be controlled or adjusted for.

3

Analyze the coffee and pancreatic cancer scenario

Identifies confounding

An apparent statistical association is eliminated upon stratification. The third variable (smoking) is linked to both the exposure and the outcome but is not on the causal pathway.

4

Analyze the diet study dropout scenario

Identifies attrition bias

Differential loss to follow-up where dropouts have a different outcome trajectory (lack of efficacy) than those who remain in the trial distorts the final study results.

5

Analyze the congenital anomaly interview scenario

Identifies recall bias

Individuals with an adverse outcome (affected infant) recall past exposures differently or more intensely than healthy controls, leading to a differential measurement error.

Key Concept

Identifying threats to validity in epidemiological studies, distinguishing between systematic errors (biases), confounding variables, and natural biological interactions.

Question 14Question →

A team of researchers is planning a case-control study to investigate a suspected association between a popular herbal sleep supplement and the development of acute drug-induced liver injury (DILI). The investigators are concerned that concurrent alcohol consumption, which is a known independent risk factor for liver injury and may also correlate with the use of sleep aids, could significantly distort the observed association. They wish to proactively implement methodological strategies at various stages of the research process to address this extraneous variable. Which of the following techniques are valid approaches for controlling the effect of concurrent alcohol consumption in this study? (Select all that apply)

Select all that apply

Restricting study enrollment exclusively to individuals who report complete abstinence from alcohol.

Matching each DILI case with a healthy control subject who falls into the exact same category of weekly alcohol intake.

Utilizing a multivariable logistic regression model to statistically adjust for alcohol consumption during data analysis.

Reporting the crude odds ratio rather than stratum-specific odds ratios to provide a summary estimate of the overall effect.

Evaluating the positive predictive value of the sleep supplement to determine the exact probability of it causing liver injury.

Show answer & explanation

Answer: Restricting study enrollment exclusively to individuals who report complete abstinence from alcohol.; Matching each DILI case with a healthy control subject who falls into the exact same category of weekly alcohol intake.; Utilizing a multivariable logistic regression model to statistically adjust for alcohol consumption during data analysis.

Answer

The valid approaches to control for confounding are restricting enrollment to non-drinkers, matching cases and controls by alcohol intake, and using multivariable logistic regression to adjust for alcohol consumption during data analysis.

Confounding occurs when an extraneous variable is associated with both the exposure and the outcome, creating a false association or masking a true one. Researchers have five primary tools to combat this: randomization, restriction, and matching (applied during study design); and stratification and multivariable regression (applied during data analysis). Restricting the study to a single group (e.g., only non-drinkers) eliminates the variable entirely. Matching ensures cases and controls have equal baseline distributions of the confounder. Multivariable regression allows statisticians to mathematically adjust the odds ratio to account for the confounder's impact.

Step-by-Step Solution

1

Identify the primary epidemiological threat described in the clinical scenario.

The scenario describes alcohol consumption as a variable associated with both the exposure (supplement use) and the outcome (DILI) without being on the causal pathway, defining it as a classic confounder.

Recognizing the variable as a confounder determines the appropriate statistical and methodological tools required to handle it.

2

Determine which techniques can control for confounding during the study design phase.

Randomization, restriction (excluding certain groups), and matching are the standard design-phase methods for controlling confounders.

Applying controls before data collection ensures that the confounding variable is equally distributed or entirely eliminated from the study population.

3

Determine which techniques can control for confounding during the data analysis phase.

Stratification (calculating stratum-specific measures) and multivariable regression modeling are the standard analysis-phase methods for addressing confounders.

These techniques mathematically adjust the data to reveal the independent association between the exposure and the outcome.

4

Evaluate the given options against the established methods for confounding control.

Restriction, matching, and multivariable logistic regression are all valid techniques. Reporting a crude odds ratio and calculating positive predictive value are incorrect approaches.

Only the methods that actively remove, balance, or statistically adjust for the confounding variable fulfill the researchers' goals.

Key Concept

Confounding variables can be controlled using specific methodological strategies in either the design phase (randomization, restriction, matching) or the analysis phase (stratification, multivariable regression) of a clinical study.

Question 15Question →

A state department of public health investigates an outbreak of a novel respiratory virus in a long-term care facility. On November 1, the facility houses 120 residents. Medical records indicate that 20 residents had previously contracted and recovered from the virus during a smaller wave in September, conferring confirmed immunity.

On November 5, an outbreak begins when a resident develops symptoms. Over the next 14 days, a total of 15 new cases of the virus are diagnosed among the residents. During this period, 3 of the newly infected residents die from respiratory failure.

Which of the following best represents the attack rate for the November outbreak among the residents?

3.0\%

12.5\%

14.3\%

15.0\%

20.0\%

Show answer & explanation

Answer: $15.0\%$

Answer

The attack rate is

15.0\%

.

The correct answer accurately calculates the attack rate by identifying 15 new cases and dividing them by the 100 susceptible residents. The 20 residents with prior immunity are correctly subtracted from the total population of 120 to determine the true population at risk.

Step-by-Step Solution

1

Determine the number of new cases during the outbreak period.

There are 15 new cases.

The numerator for an attack rate is the incident (new) cases occurring during the specified time period.

2

Calculate the population at risk at the beginning of the outbreak.

Total residents (120) - Immune residents (20) = 100 residents at risk.

The denominator for attack rate (a form of cumulative incidence) must only include susceptible individuals. Those who are already immune or already have the disease cannot become incident cases and must be excluded.

3

Calculate the attack rate.

15 / 100 = 0.15

or

15.0\%

.

Dividing the new cases by the susceptible population yields the proportion of the at-risk population that contracted the disease.

Key Concept

The attack rate is a specific type of cumulative incidence used during outbreaks, calculated by dividing the number of new cases by the total population at risk (excluding immune or non-susceptible individuals) at the beginning of the outbreak period.

Question 16Question →

A regional health department is evaluating a novel two-tiered screening protocol for a tick-borne pathogen endemic to the area. Epidemiological data indicates that the baseline prevalence of the infection in the target demographic is 10%.

The proposed protocol mandates an initial enzyme immunoassay (EIA). Only individuals who yield a positive result on the EIA will proceed to undergo a confirmatory immunoblot assay. The testing pathway is considered positive only if both assays yield positive results.

The performance characteristics of the individual assays are established as follows:
- Enzyme immunoassay: Sensitivity = 90%, Specificity = 80%
- Immunoblot assay: Sensitivity = 80%, Specificity = 90%

Assuming the two assays are conditionally independent, which of the following best represents the probability that an individual who tests positive on both sequential tests actually harbors the infection?

33%

72%

80%

97%

98%

Show answer & explanation

Answer: 80%

Answer

80%

The probability that an individual with positive results on both tests actually has the infection is the Positive Predictive Value (PPV) of the sequential testing strategy. In a population of 1,000 individuals with a 10% prevalence, 100 have the infection and 900 do not. After the first test (90% sensitivity, 80% specificity), there are 90 true positives and 180 false positives. Only these 270 individuals proceed to the second test. After the second test (80% sensitivity, 90% specificity), 72 of the true positives remain positive (

90 \times 0.80

), and 18 of the false positives test positive again (

180 \times 0.10

). The PPV is the number of true positives divided by the total number of positives:

72 / (72 + 18) = 72 / 90 = 0.80

, or 80%.

Step-by-Step Solution

1

Calculate the initial number of diseased and healthy individuals

100 diseased and 900 healthy individuals

Establishing a hypothetical cohort of 1,000 individuals based on the 10% prevalence simplifies the sequential probability calculations.

2

Determine the outcomes of the initial enzyme immunoassay (EIA)

90 True Positives (100 * 0.90) and 180 False Positives (900 * 0.20)

Because the protocol is sequential, only these 270 individuals who test positive on the EIA will proceed to the confirmatory test.

3

Determine the outcomes of the confirmatory immunoblot assay on the remaining cohort

72 final True Positives (90 * 0.80) and 18 final False Positives (180 * 0.10)

The confirmatory test is applied only to the 270 individuals who tested positive initially. The false positive rate for this specific step is 1 - 0.90 = 0.10.

4

Calculate the Positive Predictive Value (PPV) of the combined sequential strategy

PPV = 72 / (72 + 18) = 72 / 90 = 0.80 (80%)

The PPV represents the proportion of true positives among all individuals who ultimately test positive on both assays.

Key Concept

Calculating the Positive Predictive Value (PPV) in a sequential testing strategy requires applying the combined false positive and true positive rates to the baseline population prevalence.

Alternative Method

Instead of using a hypothetical cohort, this problem can be rapidly solved using Likelihood Ratios (LR). The pre-test odds are

0.10 / 0.90 = 1/9

. The LR+ for the EIA is

Sensitivity / (1 - Specificity) = 0.90 / 0.20 = 4.5

. The LR+ for the immunoblot is

0.80 / 0.10 = 8

. Because the tests are conditionally independent, the combined LR+ is

4.5 \times 8 = 36

. The post-test odds after both tests are

1/9 \times 36 = 4

. Converting odds back to probability yields

4 / (4 + 1) = 80\%

.

Estimated Time:2m 0s

Question 17Question →

Match each complex clinical research scenario with the most appropriate epidemiological study design.

Click a left item, then click its matching right item

Show answer & explanation

Answer

The correct pairings match each clinical research scenario to its defining epidemiological framework: the hospital-level randomization is a cluster randomized controlled trial; the transient trigger within-subject comparison is a case-crossover study; the targeted biomarker testing in a pre-existing cohort is a nested case-control study; and the simultaneous evaluation of two interventions with interaction analysis is a factorial randomized controlled trial.

Each scenario contains specific methodological constraints that dictate a specialized study design. Cluster randomization is required when individual randomization risks contamination. Case-crossover designs uniquely address transient environmental triggers while perfectly controlling for static confounding. Nested case-controls provide the temporal validity of a cohort study but with the cost-efficiency of a case-control design. Factorial designs are uniquely powered to evaluate interaction (synergy or antagonism) between multiple therapies.

Step-by-Step Solution

1

Analyze the first scenario regarding hospital-level randomization.

Identifies the need to prevent practice pattern contamination among physicians, pointing to a design that randomizes groups rather than individuals.

Individual randomization would fail because physicians would apply the intervention knowledge to control patients, necessitating a Cluster randomized controlled trial.

2

Evaluate the second scenario involving transient ambient particulate matter spikes.

Recognizes the use of a patient as their own control across different time windows to study an acute trigger.

When a brief exposure is suspected to immediately trigger an event, standard case-controls fail to account for static confounding. A Case-crossover study controls for all static patient characteristics.

3

Examine the third scenario regarding costly genomic sequencing in an existing 10-year cohort.

Notes that only 40 cases and 160 matched controls underwent the expensive test, despite the cohort having 50,000 patients.

This resource-saving methodology, utilizing previously collected data and biospecimens from an established cohort, defines a Nested case-control study.

4

Assess the final scenario testing a diet plan and cognitive behavioral therapy simultaneously.

Identifies the four-group allocation designed to measure independent effects and synergistic interactions.

Simultaneously investigating multiple independent variables (interventions) to calculate main effects and interaction effects is exclusively achieved via a Factorial randomized controlled trial.

Key Concept

Selection of advanced epidemiological study designs to mitigate specific methodological biases (e.g., contamination, confounding by static characteristics) and to efficiently utilize resources.

Estimated Time:1m 30s

Question 18Question →

An epidemiologist is evaluating a community intervention designed to increase physical activity among adults with type 2 diabetes. Before data collection begins, the investigator sets the maximum acceptable probability of rejecting a true null hypothesis at $0.05$ . Additionally, the probability of failing to reject a false null hypothesis is set at $0.20$ . Based on these parameters, what is the statistical power of this planned intervention study?

5\%

20\%

75\%

80\%

95\%

Show answer & explanation

Answer: $80\%$

Answer

The statistical power of the study is

80\%

.

Statistical power is defined as

1 - \beta

, where

\beta

is the probability of committing a Type II error (failing to reject a false null hypothesis). In this scenario,

\beta

is given as

0.20

. Therefore, the statistical power is

1 - 0.20 = 0.80

, or

80\%

. This represents the study's ability to successfully detect a true effect of the community intervention if one actually exists.

Step-by-Step Solution

1

Identify the probability of committing a Type II error (

\beta

) from the clinical vignette.

\beta = 0.20

The problem explicitly states that the probability of failing to reject a false null hypothesis is

0.20

.

2

Apply the mathematical formula for statistical power.

\text{Power} = 1 - \beta = 1 - 0.20 = 0.80

Statistical power is defined as the probability of correctly rejecting the null hypothesis when it is truly false.

Key Concept

Statistical power is the probability of correctly rejecting a false null hypothesis, mathematically defined as

1 - \beta

, where

\beta

is the Type II error rate.

Question 19Question →

Match each clinical research scenario with the specific epidemiological bias or confounding principle it best describes.

Click a left item, then click its matching right item

Show answer & explanation

Answer

The hospital admission scenario matches Berkson paradox; the differential dropout scenario matches Attrition bias; the severity-based prescription scenario matches Confounding by indication; the indolent tumor screening scenario matches Length-time bias; and the employed control group scenario matches Healthy worker effect.

Each scenario describes a classic epidemiological phenomenon: Berkson paradox arises from hospital admission rates; attrition bias from differential study dropout; confounding by indication from prescribing practices based on severity; length-time bias from screening capturing indolent disease; and the healthy worker effect from using employed populations as controls.

Step-by-Step Solution

1

Analyze the first scenario regarding hospital admission likelihood.

Identified as Berkson paradox.

This specific form of selection bias occurs in hospital-based studies when exposure and outcome both affect admission rates.

2

Evaluate the second scenario involving differential dropout rates.

Identified as Attrition bias.

Unequal loss to follow-up between groups selectively alters the characteristics of the remaining cohort.

3

Examine the third scenario about treatment assigned based on disease severity.

Identified as Confounding by indication.

The indication for the drug (severe disease) is associated with both the exposure and the outcome (mortality).

4

Assess the fourth scenario regarding the detection of indolent tumors.

Identified as Length-time bias.

Screening tends to catch slowly progressive diseases which naturally have better survival, creating a false impression of screening efficacy.

5

Review the fifth scenario comparing exposed workers to healthy employed workers.

Identified as Healthy worker effect.

Working populations are systematically healthier, introducing selection bias when used as a baseline for mortality or morbidity.

Key Concept

Identifying specific types of bias and confounding in epidemiological and clinical research designs.

Question 20Question →

An institutional review board is reviewing multiple research protocols. Match each proposed clinical research scenario with the epidemiological study design that best describes its methodology.

Click a left item, then click its matching right item

Show answer & explanation

Answer

The correct matches align each research scenario with its fundamental defining methodology regarding temporal direction and subject selection.

Each scenario accurately describes the core mechanics of its respective study design: case-control starts with disease; prospective cohort starts with present exposure; retrospective cohort starts with past exposure; cross-sectional takes a snapshot in time.

Step-by-Step Solution

1

Analyze the first scenario regarding idiopathic pulmonary fibrosis.

Subjects are selected based on disease outcome, and researchers look backward for exposure.

This temporal relationship (outcome to exposure) defines a case-control study.

2

Analyze the second scenario regarding exercise and cardiovascular disease.

Subjects are selected based on current exposure and followed forward in real-time for disease incidence.

This forward temporal tracking from exposure defines a prospective cohort study.

3

Analyze the third scenario regarding anti-epileptic drugs and bone fractures.

Subjects are selected based on historical exposure and followed forward in historical time for disease incidence.

This reliance on existing records to track from past exposure to subsequent outcome defines a retrospective cohort study.

4

Analyze the fourth scenario regarding migraine headaches and stress.

Exposure and outcome are measured at the exact same moment in time.

The simultaneous measurement without temporal follow-up defines a cross-sectional study.

Key Concept

Epidemiological study designs are primarily distinguished by how subjects are selected (by exposure or by outcome) and the temporal relationship between the assessment of exposure and outcome.

Estimated Time:1m 30s

Biostatistics, Epidemiology, and Medical Literature

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Alternative Method

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution